CG
PRTK

Cutler Group’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Cutler Group’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-100
Closed – – 4784
2018
Q3 		$0 Sell
100
-2,100
-95% -$21.2K ﹤0.01% 4878
2018
Q2 		$22K Sell
2,200
-781
-26% -$8.84K ﹤0.01% 2141
2018
Q1 		$38K Sell
2,981
-27,197
-90% -$405K ﹤0.01% 1862
2017
Q4 		$540K Buy
30,178
+5,851
+24% +$122K 0.02% 522
2017
Q3 		$610K Sell
24,327
-1,648
-6% -$38.4K 0.02% 555
2017
Q2 		$625K Buy
25,975
+25,089
+2,832% +$555K 0.02% 581
2017
Q1 		$17K Sell
886
-10,677
-92% -$168K ﹤0.01% 3520
2016
Q4 		$178K Sell
11,563
-5,200
-31% -$67.5K 0.01% 1386
2016
Q3 		$218K Buy
16,763
+6,876
+70% +$91.2K 0.01% 1134
2016
Q2 		$137K Buy
+9,887
New +$146K 0.01% 1425

Other funds holding PRTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
APCM
Arbiter Partners Capital Management New York $175M AUM 99.81% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Cutler Group's PRTK Position: Q4 2018 in Review

Cutler Group sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2018, closing a stake of 100 shares.

Cutler Group first reported a position in PRTK in Q2 2016 and held it in 10 quarters. The position peaked at $625K in Q2 2017. 102 funds tracked by Wall St. Rank hold PRTK as of Q4 2018.

  • Cutler Group reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Cutler Group sold 100 Paratek Pharmaceuticals, Inc. shares in Q4 2018.
  • Cutler Group first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2016 and held it in 10 quarters.
  • Cutler Group's Paratek Pharmaceuticals, Inc. position peaked at $625K in Q2 2017.
  • 102 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2018.

Based on Cutler Group's 13F filing for Q4 2018, filed 5 Feb 2019.